Reply to E. Hindié
Authors/Creators
Alexander M. M. Eggermont
Christian U. Blank
Mario Mandala
Georgina V. Long
Victoria G. Atkinson
Stéphane Dalle
Andrew M. Haydon
Andrey Meshcheryakov
Adnan Khattak, Edith Cowan UniversityFollow
Matteo S. Carlino
Shahneen Sandhu
James Larkin
Susana Puig
Paolo A. Ascierto
Piotr Rutkowski
Dirk Schadendorf
Rutger Koornstra
Leonel Hernandez-Aya
Anna Maria Di Giacomo
Alfonsus J. M. van den Eertwegh
Jean-Jacques Grob
Ralf Gutzmer
Rahima Jamal
Paul C. Lorigan
Alexander C. J. van Akkooi
Clemens Krepler
Nageatte Ibrahim
Sandrine Marreaud
Michal Kicinski
Stefan Suciu
Caroline Robert
Abstract
We thank Dr Hindié1 for her insightful comments and the pertinent question at the end of her deliberations. In our recent publication2 in the Journal of Clinical Oncology, we have demonstrated that the prolongation of recurrence-free survival (RFS) with pembrolizumab adjuvant therapy in the EORTC 1325/KEYNOTE-054 phase III trial, at a median follow-up of 3 years, is sustained and consistent in magnitude (hazard ratio [HR], 0.56) with the initially reported final analysis of this primary end point as published in 2018.3 In this trial, patients with melanoma were stratified as stage IIIA-B-C, according to the American Joint Committee on Cancer (AJCC)-7 staging system,4 with the specific prerequisite that stage IIIA patients must have a micrometastasis with a diameter > 1 mm according to the Rotterdam Criteria, to avoid a potentially large influx of patients with a very low risk of recurrence.
Document Type
Response or Comment
Date of Publication
2021
Volume
39
Issue
8
Funding Information
Merck & Co Inc
PubMed ID
33492998
School
School of Medical and Health Sciences
Copyright
free_to_read
Publisher
American Society of Clinical Oncology
Recommended Citation
Eggermont, A. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A., van den Eertwegh, A. J., Grob, J., Gutzmer, R., Jamal, R., Lorigan, P. C., van Akkooi, A. C., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., & Robert, C. (2021). Reply to E. Hindié. DOI: https://doi.org/10.1200/JCO.20.03463
Comments
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., . . . Robert, C. (2021). Reply to E. Hindié [Correspondence]. Journal of Clinical Oncology, 39(8), 944-946. https://doi.org/10.1200/JCO.20.03463